Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.5 (market cap $31.07B), while Vertex Pharmaceuticals Incorporated trades at $503.12 (market cap $122.98B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4× GE HealthCare Technologies Inc. Common Stock's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| GEHC | VRTX | |
|---|---|---|
Market Cap | $31.07B | $122.98B |
Volume | 3,443,020 | 1,155,743 |
Sector | Health | Health |
52-Week High | $88.16 | $557.96 |
52-Week Low | $59.48 | $407.90 |
Enterprise Value | $39.53B | $117.11B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 120 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Vertex Pharmaceuticals (VRTX) trades at $498.50, down 1.68% amid mixed technical signals. The stock shows strong fundamentals with $12B revenue, 35% net margins, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Technical indicators show bearish momentum with support at $496 and resistance at $512.
Outlook remains positive with 86% analyst buy ratings and $573.50 price target. Key risks include clinical trial outcomes and competitive pressures. The company's expanding pipeline and profitability provide upside potential, though near-term volatility may persist around key technical levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
